Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Brainstorm Cell Therapeutics Inc (Public, OTC:BCLI)

88 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  1. svenhedin 6 maart 2017 11:23

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    Ter voorbereiding fase 3 worden er steeds meer stappen gezet richting artsen en medische centra.
    Ik verwacht binnenkort aankondiging start fase 3 ALS.
  2. svenhedin 6 maart 2017 11:41

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    I am thrilled to join BrainStorm and advance the Phase 3 program for NurOwn to seek an effective solution for ALS patients and their families," said Dr. Kern. "I am confident that BrainStorm will become the world leader in adult stem cell therapies for neurodegenerative disorders."
  3. svenhedin 6 maart 2017 11:55

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    quote:

    sethonno schreef op 23 februari 2017 16:22:

    ik volg hem ook
    Fijn te vernemen.
    Bij aankondiging fase 3 ALS zal de koers m.i richting $6 gaan.
    Succes.
  4. svenhedin 22 maart 2017 13:54

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide an update on new developments and a corporate overview at Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum, being held on March 27th at the New York Academy of Sciences.
  5. svenhedin 30 maart 2017 09:49

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    03/29/17 10-K Annual report which provides a comprehensive overview of the company for the past year Annual Filings

    Betreft uitgebreide rapportage met stand van zaken.
    Zeker interessant leesvoer.
  6. svenhedin 30 maart 2017 17:29

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    BrainStorm Announces Financial Results for 2016 and Provides Business Update

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 30, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31, 2016.

    ir.brainstorm-cell.com/phoenix.zhtml?...

    START Fase 3 ALS wordt verwacht 2e kwartaal 2017
  9. svenhedin 3 april 2017 22:13

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    VOLUME

    1.91mil shares, +1729% compared to typical volume of 104.5k by 3:40 pm ET (15-20 min delayed).

    High Volume alert!
    Typical daily volume is 121.5k shares over the past 6 months.
  10. svenhedin 4 april 2017 16:32

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    6. BrainStorm Cell Therapeutics Inc. ( BCLI )
    Gained 13.10% to close Monday's trading at $3.54.
    News: No news
    Near-term catalysts:
    -- A planned phase III clinical trial of NurOwn in patients with Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) to be conducted at multiple sites in the U.S. and in Israel, is expected to begin enrolling patients in the second quarter of 2017. -- The Company's Memorandum of Understanding (MOU) with the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center (Ichilov Hospital) to explore the possibility of making NurOwn available to ALS patients under the provisions of Hospital Exemption regulation that was signed last month, is expected to be formalized in the first half of 2017

    Read more: www.nasdaq.com/article/gainers--loser...
  11. svenhedin 5 april 2017 20:04

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    H.K.H. Prinses Beatrix bij Jubileumsymposium WERELD PARKINSON DAG op 8 april 2017 aanwezig. We staan samen stil bij het 40-jarig bestaan van de Parkinson Vereniging Nederland.(locatie Congrescentrum Nieuwegein)
    Toegang uitsluitend na inschrijving !

    Het zal een prima idee zijn om voor 8 april de start van de 3e fase ALS aan te kondigen.
  12. svenhedin 5 april 2017 20:24

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    Zag vandaag dat de targets zijn verhoogd.
    Was $9,50 (via $6)
    Nu $13 (via $8 en $10,50)

    12-Month Price Target Range

    8

    Consensus

    10.5

    13

    4.47
    Previous Close

    Graph Key

    The 12-month Consensus Price Target is the average of individual price target estimates submitted by covering sell-side analysts.

    Read more: www.nasdaq.com/symbol/bcli/analyst-re...
  14. svenhedin 18 april 2017 11:34

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    . BrainStorm Cell Therapeutics Inc. ( BCLI )
    Gained 10.41% to close Monday's trading at $4.03.
    News: No news
    Near-term catalysts:
    -- A planned phase III clinical trial of NurOwn in patients with Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) to be conducted at multiple sites in the U.S. and in Israel is expected to begin enrolling patients in the second quarter of 2017. -- The Company's Memorandum of Understanding (MOU) with the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center (Ichilov Hospital) to explore the possibility of making NurOwn available to ALS patients under the provisions of Hospital Exemption regulation that was signed last month, is expected to be formalized in the first half of 2017

    Read more: www.nasdaq.com/article/gainers--loser...
  15. svenhedin 19 april 2017 21:24

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    BrainStorm Announces Publication of NurOwn® Autism Research Study
    Preclinical Findings Show Potential for Human Benefit

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, April 19, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that a preclinical study evaluating the use of NurOwn® mesenchymal stem cells in a mouse model of autism was published in the April issue of the journal Behavioural Brain Research [Perets N. et al. Epub ahead of print, PMID: 28392323]. The publication, entitled "Long Term Beneficial Effect of Neurotrophic Factors-Secreting Mesenchymal Stem Cells Transplantation in the BTBR Mouse Model of Autism, was authored by Prof. Daniel Offen, Head of Tel Aviv University's Translational Neuroscience Laboratory, Sackler School of Medicine, and Brainstorm's Chief Scientific Advisor.
  17. svenhedin 24 april 2017 19:24

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 20 feb 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    Brainstorm Cell Therapeutics Set To Begin Phase 3 In Amyotrophic Lateral Sclerosis

    Apr.18.17 | About: BrainStorm Cell (BCLI)

    Strong Bio
    Long only, biotech, growth, contrarian


    (467 followers)
    Summary
    Phase 2 AML data in July met primary endpoints.
    City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn adult stem cells.
    With 10 million in cash on hand, an offering or partnership is needed.
    Brainstorm Cell Therapeutics, (NASDAQ:BCLI) is a biotechnology company developing stem cell therapies to treat neurodegenerative diseases. This technology converts mesenchymal stem cells into a proprietary drug delivery system, called NurOwn, designed to support damaged neurons. NurOwn cells dampen the immune system and secrete growth factors that help damaged neurons survive.
    Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into bone, cartilage, muscle, and fat cells, but do not differentiate into blood cells or their precursors. Early clinical uses for MSCs included purposes of enhancing bone marrow grafts such as controlling graft versus host disease (Prochymal, remestemcel-L, was approved for use in Canada and New Zealand for steroid-refractory graft versus host disease, made by Osiris), but it was later discovered that MSCs are able to inhibit the immune system inflammation in other specific useful ways. Now, studies investigating the use of MSCs in inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, cardiovascular disease, stroke, kidney disease and many others are ongoing.
    BCLI's patented NurOwn (publications link) technology makes use of MSCs by growing them under specific and proprietary conditions to stimulate secretion of a variety of neurotrophic factors. These factors support the survival and signal conduction of neurons and can be used to treat neurodegenerative diseases. Neurotrophic factors also have immunomodulatory characteristics. Factors of interest secreted by MSCs include protein signaling biomolecules BDNF, VEGF, HGF,and GDNF, which all primarily exert effects via tyrosine kinase signaling. Animal models show that NurOwn cells can help protect neurons from toxic damage in amyotrophic lateral sclerosis, sciatic nerve injury, Parkinson's disease, multiple sclerosis, optic nerve ischemia, and Huntington's disease.

    ALS, also called Lou Gehrig's disease or motor neuron disease, is a specific neurodegenerative disease that destroys neurons causing lack of control of voluntary muscles. The cause of the disease is not fully known, though there is a genetic component in a 5-10% subset of the patient population. There is no cure. Sanofi produces a drug to treat AML, Riluzole (Rilutek, Teglutik), which delays the onset of ventilator-dependence and may increase survival by two to three months. The annual market for AML is expected to reach about 750 million dollars by 2018, however the Rilutek patent expiration is expected to decrease the total market starting in 2019.
    2016 has been a year of progress for BCLI in ALS and phase 2 trials. According to CEO Chaim Lebovits, BCLI announced positive top-line phase 2 data of NurOwn in treatment of ALS, demonstrating the potential of this therapy not only to halt but also reverse ALS disease progression. Response rates (based on ALSFRS-R) responder analysis of halt or reverse of disease progression were higher in NurOwn-treated subjects compared to placebo at all time points to 24 weeks. The treatment was well tolerated and no serious adverse effects were observed. FDA agreed to accept the key elements of the phase 3 program to support a biologic license application for NurOwn. BCLI will enter phase 3 clinical trials in second quarter 2017 in the U.S. and Israel.
    BCLI is seeking early regulatory approval for NurOwn for ALS in Canada, and has made efforts to make NurOwn available for ALS patients in Tel Aviv as a hospital exemption product. The company has also taken on some new personel to strengthen its management team. A closer look at the clinical trial sites for the company is encouraging as well, which includes Mayo clinic and Massachusetts General (both are top tier sites, with Mayo being ranked #1 and MSG ranked #4 in neurology according to US News and World Report). In addition the company was able to pull down a 1.5 million dollar non-dilutive grant from the Israeli government.

    So investors are asking, is it time to go long on Brainstorm? As this article states (and its a gem), the strongest therapeutic effect was achieved in those patients whose disease was progressing the fastest (about half the patients in the study). This could lead to physicians being more likely to choose NurOwn for their patients. In addition the article does a nice comparator with Bluebird and Sarepta, two companies with neurodegenerative disorder gene and cell therapies with similar efficacy. The market values Bluebird and Sarepta with much higher market cap, making BCLI a great candidate for a contrarian long position.
    This biotechnology chart has an unusual ascending pattern with good support over the last few years. In addition the market cap for BCLI is moving up from approximately 50 million to 70 million in recent months. That being said Strong Bio would wait until a partner or dilutive event materializes to take a long position. With phase 3 initiation now upon BCLI, this is a timely biotechnology long position candidate once they demonstrate they have funding to last through phase 3 trials. That being said, it is hard to object to taking a position as an angel investor if it helps the company and patients in this disease. It certainly appears as if the investment will be rewarded in coming years, if phase 3 data is as good as the pooled data for early trials.
    Risks include FDA clinical trial failure, adverse events leading to trial delays, and standard biotechnology potential pitfalls. Dilution is certainly a risk for investors. Competition in the stem cell and neurodegenerative disease fields with larger and better funded companies should be noted as a risk as well, with market penetration being a significant challenge.
    Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
    I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
    About this article:Expand

    1,430 people get BCLI breaking news and analysis by email alert
    Get email alerts on BCLI

    Recommended for you:

    BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate

88 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.281
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.064
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.861
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.141
Aedifica 2 828
Aegon 3.257 319.986
AFC Ajax 537 7.010
Affimed NV 2 5.734
ageas 5.843 109.775
Agfa-Gevaert 13 1.853
Ahold 3.536 73.977
Air France - KLM 1.024 34.302
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.681
Alfen 12 15.960
Allfunds Group 3 1.122
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 324
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.755
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.144
AMG 965 125.575
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 379
Antonov 22.632 153.605
Aperam 91 14.101
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.570
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.087
Aroundtown SA 1 175
Arrowhead Research 5 9.247
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.523
ASML 1.762 76.395
ASR Nederland 18 4.117
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.615
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.657

Macro & Bedrijfsagenda

  1. 18 april

    1. NSI Q1-cijfers
    2. Sipef Q1-cijfers
    3. Sligro Q1-cijfers
    4. NL werkloosheid maart
    5. Deliveroo trading update
    6. Easyjet trading update
    7. Econocom Q1-cijfers
    8. PostNL €0,03 ex-dividend
    9. Procter & Gamble Q1-cijfers
    10. VS steunaanvragen - wekelijks
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda